Centre Amends Drugs Rules, 1945 to Ensure Uniform Regulation of Advanced Cell and Gene Therapies

Why in news

The Central Government has amended the Drugs Rules, 1945, to bring advanced medical technologies like Cell or Stem Cell derived products, Gene therapeutic products, and Xenografts under the Centrally License Approving Authority (CLAA) framework, aiming for uniform regulation.

Exam relevance

GS2, GS3 · Governance, Science & Technology, Economy · Prelims · Mains

Key facts

1. The Drugs Rules, 1945 have been amended by the Central Government.
2. The amendment brings Cell or Stem Cell derived products, Gene therapeutic products, and Xenografts under the Centrally License Approving Authority (CLAA) framework.
3. These advanced medical technologies will now have uniform regulation.
4. The Drugs and Cosmetics Act already places certain critical drugs and biological products under joint regulatory supervision of Central and State regulators.
5. Existing categories under joint supervision include vaccines, large volume parenterals (IV solutions > 100 ml), and r-DNA based medicines.
6. Cell or Stem Cell derived products include stem cell-based regenerative treatments and CAR-T cell therapies used for blood cancers.
7. Gene therapeutic products are used for genetic disorders and cancers.
8. Xenografts are animal tissue-derived products like heart valves for human transplantation.

Prelims pointers

• The Drugs Rules, 1945 have been amended.
• Cell or Stem Cell derived products, Gene therapeutic products, and Xenografts are now under the CLAA framework.
• Vaccines, large volume parenterals, and r-DNA based medicines are existing categories under joint regulatory supervision.
• The Drugs and Cosmetics Act provides the legal basis for such regulations.

Mains practice question

Discuss the significance of the recent amendments to the Drugs Rules, 1945, in regulating advanced cell and gene therapies in India. What are the potential implications for public health and the biotechnology sector?

Static linkage

The amendment is made under the Drugs and Cosmetics Act, which governs the regulation of drugs and cosmetics in India. The CLAA framework is part of the existing regulatory structure for critical drugs and biological products, ensuring a balance between central and state oversight.

Significance

This amendment is significant for strengthening regulatory oversight of emerging medical technologies. By bringing advanced cell and gene therapies under a uniform regulatory framework via the CLAA, it aims to ensure quality, safety, and efficacy of these novel treatments. This will likely foster innovation and patient access to cutting-edge medical solutions while maintaining robust regulatory standards, potentially impacting the pharmaceutical and biotechnology sectors.